Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Vaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting ...

As preventable infections like measles threaten to become endemic again in the US, researchers whose government grants were ...

Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews ...

Key Takeaways Moderna and other vaccine stocks fell Monday after the Food and Drug Administration's vaccine chief, Peter ...

Dr. Peter Marks, a veteran of the agency, wrote that undermining confidence in vaccines is irresponsible and a danger to ...

Just two days after Democrat Joe Biden was declared the winner of the 2020 presidential election, drugmaker Pfizer announced ...

Not just IgG4 antibodies that become predominant in the many-jabbed, but also lesser studied IgG2, researchers find. NIH ...

After decades of failed attempts, scientists were optimistic that a new generation of HIV vaccine candidates would finally ...

"An adversarial collaboration on vaccines could serve as a model," write Drs. Christopher M. Worsham and Anupam B. Jena.

Federal prosecutors in Manhattan are probing a claim by GSK that Pfizer delayed announcing its COVID shot's success in 2020 ...

Trump has claimed the company delayed an announcement for its vaccine until after the 2020 presidential election.